Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept plus NSAID in early non-radiographic axial spondyloarthritis
NL-OMON38358Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etanercept in non-radiographic axial spondyloarthritis (nr-axSpA) (3 arms), sponsored by Pfizer. Primary endpoint: ASAS40 response at week 12. Started Dec 2011; status: active, not recruiting.
02
Drugs
etanercept
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON38358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38358.